nm23-H1与CD44v6在非小细胞肺癌中的表达及临床意义  

Expression and clinical significance of nm23-H1 and CD44v6 in non-small cell lung cancer

作　　者：王子彤[1] 张海青 李世业[1] 

机构地区：[1]北京市胸部肿瘤结核病医院胸外科,101149 [2]北京市胸部肿瘤结核病医院病理科,101149

出　　处：《中国肺癌杂志》2002年第4期278-281,共4页Chinese Journal of Lung Cancer

摘　　要：目的　探讨nm2 3 H1与CD44v6在非小细胞肺癌 (NSCLC)中的表达及其临床意义。方法　采用免疫组化SP法检测 14 7例NSCLC标本中nm2 3 H1、CD44v6的表达。结果　全组nm 2 3 H1阳性率为62 .6% (92 /14 7) ,其中Ⅰ +Ⅱ期与Ⅲ +Ⅳ期 ,N0 组与N1～ 3 组间阳性率无显著性差异 (P >0 .0 5 ) ,高、中分化组与低分化组 ,腺癌与鳞癌 ,生存期低于 3年组与生存期超过 3年组间阳性率有显著性差异 (P <0 .0 5 )。CD44v6阳性率为 63 .9% (94/14 7) ,其中Ⅰ +Ⅱ期与Ⅲ +Ⅳ期 ,N0 组与N1～ 3 组间阳性率无显著性差异 (P >0 .0 5 ) ,高、中分化组与低分化组 ,鳞癌与腺癌 ,生存期低于 3年组与生存期超过 3年组间阳性率有显著性差异(P <0 .0 5 )。nm2 3 H 1(+ )CD44v6(-)者的预后明显好于nm 2 3 H1(-)CD44v6(+ ) (P <0 .0 1)。结论　nm2 3 H 1和CD44v6的表达与NSCLC的分化程度、病理类型及预后密切相关 ,与PTNM分期及淋巴结是否转移无关。nm 2 3 H1(+ )CD44v6(-)者比nm 2 3 H1(-)CD44v6(+ )的预后佳。Objective To study the role of nm23 H1 and CD44v6 gene in non small cell lung cancer (NSCLC). Methods Expressions of nm23 H1 and CD44v6 genes were analyzed in 147 cases of NSCLC by SP immunohistochemistry method. Results The overall positive rate of nm23 H1 staining was 62.6% (92/147). Significant differences in the positive rate of nm23 H1 were found between well and poor differentiated groups [68.6% (83/121) [WTBX]vs 34.6% (9/26)], and between adenocarcinoma and squamous cell carcinoma , and between adenocarcinoma and squamous cell carcinoma [78.8% (52/66) [WTBX]vs 50.8% (32/63) ] ( (P<0.05), but not between stage Ⅰ+Ⅱ and stage Ⅲ+Ⅳ [ 65.3% (62/95) [WTBX]vs 57.7% (30/52) ], and between N0 and N1 3 , and between N0 and N1 3 [64.7% (55/85) [WTBX]vs 59.7% (37/62) ]( ( P>0.05). The positive rate of nm23 H1 of patients who survived for more than 3 years was 71.4% (55/77), which was significantly higher than 52.9% (37/70) of patients who survived for less than 3 years (χ 2=5.4, P<0.05). For CD44v6, the overall positive rate was 63.9% (94/147). Significant differences in the positive rate of CD44v6 were found between well and poor differentiated groups [68.6% (83/121) [WTBX]vs 42.3% (11/26)], and between adenocarcinoma and squamous cell carcinoma , and between adenocarcinoma and squamous cell carcinoma [53.0% (35/66) [WTBX]vs 77.8% (49/63) ] ( (P<0.05), but not between stage Ⅰ+Ⅱ and stage Ⅲ+Ⅳ [ 66.3% (63/95) [WTBX]vs 59.6% (31/52) ], and between N0 and N1 3 , and between N0 and N1 3 [63.5% (54/85) [WTBX]vs 64.5% (40/62) ]((P>0.05). The positive rate of CD44v6 of patients who survived for more than 3 years was much lower than that of patients who survived for less than 3 years (43/74 vs 51/70, P< 0.01 ). The 3 year survival rate in patients with nm23 H1(+)CD4v6(-) was significantly higher than those with nm23 H1(-)CV44v6(+) (22/32 vs 11/34, P<0.01). Conclusion There are some relationships among expressions of nm23 H1 and CD44v6 in NSCLC and cell differentiation, histolog

关 键 词：NM23-H1 CD44V6 非小细胞肺癌 临床意义 预后 免疫组化S初学者 肿瘤分化 

分 类 号：R734.2[医药卫生—肿瘤]